FocusCystic Fibrosis

CFTR Potentiators: Not an Open and Shut Case

Science Translational Medicine  23 Jul 2014:
Vol. 6, Issue 246, pp. 246fs27
DOI: 10.1126/scitranslmed.3009674

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

Insights into the positive and negative effects of drugs to treat cystic fibrosis (CF) patients with a common mutation raise questions about how we discover and translate CF therapeutics (Veit et al. and Cholon et al., this issue).

View Full Text